Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Retinal Gene Therapy Market Snapshot

According to Future Market Insights research, during the projected period, the global retinal gene therapy market is expected to grow at a CAGR of 9.2%. The market value is projected to increase from US$ 97.3 Million in 2023 to US$ 235.4 Million by 2033. The retinal gene therapy market was valued at US$ 89.9 Million at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 8.2% in 2023.

Market Outlook:

Data Points Market Insights
Market Value 2022 US$ 89.9 Million
Market Value 2023 US$ 97.3 Million
Market Value 2023 US$ 235.4 Million
CAGR 2023 to 2033 9.2%
Share of Top 5 Countries 55.7%
Key Players Gyroscope Therapeutics (Novartis), Applied Genetic Technologies Corporation (AGTC), Spark Therapeutics, Adverum Biotechnologies, REGENXBIO Inc., Biogen Inc., Nightstar Therapeutics, MeiraGTx Holdings plc, GenSight Biologics, RetroSense Therapeutics, Second Sight Medical Products, Oxford Biomedica, Hemera Biosciences, Adverio Pharmaceuticals

Retinal gene therapy is a treatment approach that aims to restore or replace the faulty or missing genes that cause inherited retinal diseases. Inherited retinal diseases like Retinitis Pigmentosa or Leber Congenital Amaurosis occur due to a genetic mutation that leads to the degeneration of photoreceptor cells in the retina, ultimately leading to vision loss or blindness.

Retinal gene therapy is a promising approach as it has the potential to provide a one-time treatment that could help patients with inherited retinal diseases to maintain or restore their vision. However, this treatment is still in the early stages of development and is not yet available as a standard treatment.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Retinal Gene Therapy Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

Sales of the retinal gene therapy grew at a CAGR of 7.7% between 2017 and 2022. The global market for retinal gene therapy contributes around 1.3% to the US$ 7.0 Billion gene therapy market in 2022.

The prevalence of inherited retinal diseases like Retinitis pigmentosa, Leber Congenital Amaurosis, and Choroideremia is increasing globally. This rise in the prevalence of these diseases is driving demand for new treatment options.

  • As per an article published in NCBI, 2023, around one in 5000 people worldwide are carriers of non-syndromic retinitis pigmentosa, which has a prevalence rate of one in 1000. Men are impacted slightly more often than women because men express the X-linked variant more frequently.
  • According to an article reported in the American Academy of Ophthalmology, 2022, One in 50,000 to one in 100,000 people are believed to be affected by the unusual chorioretinal dystrophy known as choroideremia. The dystrophy typically affects men because of its X-linked etiology, while it can also affect women in rare cases or as asymptomatic carriers.

There is currently no cure for inherited retinal diseases. Existing treatments focus mainly on slowing disease progression, but they do not halt or reverse the damage already done. Retinal gene therapy has the potential to offer a once-in-a-lifetime cure or long-term solution for these debilitating diseases. As such, this significant unmet need is a key driver of continued development and commercialization efforts.

Significant advancements in surgical methods required for delivering altered genes to the retinal tissue have been made over the last two decades, which has facilitated the development of novel and revolutionary treatment approaches.

  • Unlike traditional treatments like medications or surgery, retinal gene therapy aims at correcting the underlying genetic defect in the patient. This approach has the potential to provide a one-time cure that can halt, or in some cases possibly restore, vision loss permanently.
  • Certain gene therapies in development are designed as low frequency treatments designed to limit the number of administrations beyond the initial treatment. The success of Luxturna has shown the potential of low frequency therapies in the field.

Owing to such factors, FMI projects the global market to grow over a CAGR of 9.2% through the forecast years.

What are the Key Opportunities in the Market?

The technological advancements in gene editing, viral vector development and delivery systems are enabling the development of more efficient and safe gene-based therapies. This has led to a surge in research and development activities aimed at exploring the potential of gene therapies for inherited retinal diseases.

  • Gene editing technologies like CRISPR/Cas9 and Zinc Finger Nucleases (ZFNs) have enabled the precise and efficient editing of DNA, allowing for specific genes to be targeted and corrected.

Viral vectors, which are used to deliver genes into target cells, are key to gene therapy. The development of safer and more efficient viral vectors has been a major area of focus for gene therapy. For example, Adeno-associated virus (AAV) vectors have become the most commonly used viral delivery system for genetic therapies in humans.

  • For example, Adeno-associated virus (AAV) vectors have become the most commonly used viral delivery system for genetic therapies in humans. AAV vectors have been underpinning several FDA-approved gene therapies including Luxturna, a one-time gene therapy for the treatment of genetic vision loss, showing the potential of this vector technology.

Governments and private entities worldwide are increasingly investing in gene therapies for inherited diseases, including retinal disease. This funding increase has encouraged continued research and development, accelerating the development of gene therapies while providing financial support for clinical trials and commercialization efforts.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are the Potential Factors Capable of Restraining the Growth of Global Market?

The probable obstruction to growth is affordability, as the cost associated with multiple dosages is one of the major concerns for patients and caregivers, as it would involve high costs and reimbursement procedures.

There remains regulatory uncertainty around reimbursement and market access for gene therapy products which also hinders growth, with potential regulatory challenges associated with gene therapies, affordability, access by health systems, and access to specialized care providers affecting the commercial uptake.

Retinal gene therapy being an early-phase developmental technology, the development process involves significant research and development costs, which require immense investments of time, money and resources.

The number of potential patients with inherited retinal diseases is limited, meaning the market size for these treatments is small. Also, awareness among healthcare professionals regarding this therapy is still limited in several low- to middle-income economic countries.

Inherently there are concerns surrounding gene therapy safety even after approval whereby follow up must take place due to potential side effects that may emerge.

Overall, these factors are capable of restraining the expansion of the market in the future as well.

Country-wise Insights

What Makes the USA a Dominating Market in the Retinal gene therapy Industry?

The USA contributed the most in the North America and made a profitable market, holding about 34.2% in the global market by the end of year 2022.

Retinal gene therapy research in the USA is being conducted by many renowned research institutions and companies, which have made significant progress in the field over the last decade. These technological advancements have given the USA market a leading edge in Retinal gene therapy development.

Likewise, the USA government also provides significant funding towards research and development in the area of gene therapy, with a major portion of this going towards Retinal gene therapy.

What is Making Germany to Grow Significantly in the European Market?

Germany is one of the leading countries in Europe, with a significant growth rate of 7.5% over the forecast period.

Germany, together with the United Kingdom and France, has the highest incidence of age-related macular degeneration (AMD)-related blindness and also has a large patient pool inflicted with inherited retinal diseases. This patient pool is likely to create demands for gene therapies for the treatment of their visual abnormalities, consequently, this may provide companies to have a sizeable and established market for their products.

How China is Emerging as a Prominent Market in the Global Industry?

China is projected to be the most attractive market in the East Asia market, accounting for the global market share of around 6.5% in 2022.

With significant advances in gene therapy manufacturing technology, China is taking advantage of its affordable domestic manufacturing of gene therapy.

Many Chinese domestic companies are research and development focused on the development of gene therapies for inherited retinal diseases in the country. The Chinese government offers significant support to life science research, development, and production, which has led to a surge in domestic research and development within the country.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Segment Has Dominated the Indication category?

The Stargardt disease accounted for the dominant share of 32.8% in the global market in 2022 and expected to expand at a CAGR of 9.7% throughout the forecast period.

The growing prevalence of Stargardt disease globally, particularly in developed economies, has created high demand for retinal gene therapy worldwide. The potential to restore visual function in patients with inherited retinal diseases like Stargardt disease has led to a surge in research and development in the area, with many companies working on retinal gene therapy to help address the high unmet demand for innovative treatments.

Which End User Held the Major Chunk of the Market?

Hospitals held the significant share in the global market as a distribution channel with holding about 43.6% of the overall market by the end of 2022.

Retinal gene therapy is a highly technical procedure and requires specialization and expertise in delivering the therapy, making hospitals with specialized care facilities a natural fit as the leading end-users of the therapy.

Hospitals have the advantage of direct patient access which can be crucial for high-end gene therapies where patients require hospitalization to deliver the treatment. Retinal gene therapy could require such specialized inpatient care before the patient is transitioned to at-home care.

Competitive Landscape

Due to the high market concentration and sub-segmented market, companies are relying on research and development of novel therapies to deliver the treatment more effectively and efficiently. Companies such as Janssen Biotech, have currently entered the market and continue to invest heavily in research and development.

Overall, research and development, strategic collaborations, regulatory approvals, and international expansion remain top priorities for companies looking to increase their market share in the retinal gene therapy industry, with competition driving innovation, and making the therapy available and more cost-effective on a wider scale.

For instance:

  • In December 2021, Ocugen, Inc. announced that the USA FDA approved its application for an investigational new drug to start a phase 1/2 clinical evaluation for the gene therapy potential candidate OCU400 for the treatment of inherited retinal degeneration.
  • In October 2021, GenSight Biologics announced that the FDA granted GS030 optogenetic therapy for the medical treatment of retinitis pigmentosa fast track status.

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the retinal gene therapy market, which are available in the full report.

Report Scope as per Retinal Gene Therapy Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis USD Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, GCC Countries, Northern Africa
Key Segments Covered Indication, End User, and Region
Key Companies Profiled
  • Gyroscope Therapeutics (Novartis)
  • Applied Genetic Technologies Corporation (AGTC)
  • Spark Therapeutics
  • Adverum Biotechnologies
  • REGENXBIO Inc.
  • Biogen Inc.
  • Nightstar Therapeutics
  • MeiraGTx Holdings plc
  • GenSight Biologics
  • RetroSense Therapeutics
  • Second Sight Medical Products
  • Oxford Biomedica
  • Hemera Biosciences
  • Adverio Pharmaceuticals
Report Coverage Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Market Segments Covered in Retinal Gene Therapy Market Industry Analysis

By Indication:

  • Leber Congenital Amaurosis (LCA)
  • Stargardt Disease
  • Choroideremia
  • X-linked Retinitis Pigmentosa (RP)
  • Others

By End User:

  • Hospitals
  • Academic & Research Institutes
  • Ophthalmic Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

How Big is the Retinal Gene Therapy Market?

The market is valued at US$ 97.3 million in 2023.

How Big will the Retinal Gene Therapy Market be by 2033?

The market is estimated to reach US$ 235.4 million by 2033.

Which Countries Dominate the Global Market?

The United States, Japan, and China dominate the global market.

What is the Growth Forecast for Retinal Gene Therapy Market?

The market is forecast to register a CAGR of 9.2% through 2033.

What are the Key Opportunities in the Retinal Gene Therapy Market?

The technological advancements in gene editing, viral vector development, and delivery systems enable the development of more efficient gene-based therapies.

Table of Content

1. Executive Summary

  1.1. Global Market Outlook

  1.2. Demand Side Trends

  1.3. Supply Side Trends

  1.4. FMI Analysis and Recommendations

2. Market Overview

  2.1. Market Coverage / Taxonomy

  2.2. Market Definition / Scope / Limitations

  2.3. Inclusions/Exclusions

3. Market Trends 

  3.1. Key Trends Impacting the Market

  3.2. Product Innovation / Development Trends

4. Value Added Insights

  4.1. Disease Epidemiology by Region

  4.2. Treatment Adoption / Usage Analysis, by Region

  4.3. Patient Treatment Regime

  4.4. Regulatory Scenario

  4.5. PESTEL Analysis

5. Market Background

  5.1. Macro-Economic Factors

    5.1.1. Global Healthcare Expenditure Outlook

    5.1.2. Global Pharmaceutical Industry Outlook

    5.1.3. Global Gene Therapy Market Outlook

  5.2. Forecast Factors - Relevance & Impact

    5.2.1. Prevalence Rate of Genetic Disorders Like Retinitis Pigmentosa and Leber Congenital Amaurosis

    5.2.2. Increasing Awareness Among Physicians and Patients About the Benefits of Gene Therapy for Retinal Diseases

    5.2.3. Technological Advancements in Gene Delivery Platforms Like Viral Vectors or Gene Editing Tools

    5.2.4. Regulatory Approvals and Increasing Research & Development Activities to Advance Gene Therapy Treatments for Various Diseases

    5.2.5. Developing Healthcare Infrastructure in Emerging Countries

    5.2.6. Rising Collaborations and Partnerships Among Research Organizations to Develop Gene Therapies

    5.2.7. Increasing Investments in the Gene Therapy Market by Pharmaceutical Companies and Government Bodies

  5.3. Market Dynamics

    5.3.1. Drivers

    5.3.2. Restraints

    5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Mn) Analysis 2017 – 2022 and Forecast, 2023 – 2033

  6.1. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

  6.2. Historical Market Value (US$ Mn) Analysis, 2017 – 2022

  6.3. Current and Future Market Value (US$ Mn) Projections, 2023 – 2033

    6.3.1. Y-o-Y Growth Trend Analysis

    6.3.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2017 – 2022 and Forecast 2023 – 2033, By Indication

  7.1. Introduction / Key Findings

  7.2. Historical Market Size (US$ Mn) Analysis By Indication, 2017 – 2022

  7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2023 – 2033

    7.3.1. Leber Congenital Amaurosis (LCA)

    7.3.2. Stargardt Disease

    7.3.3. Choroideremia

    7.3.4. X-linked Retinitis Pigmentosa (RP)

    7.3.5. Others

  7.4. Market Attractiveness Analysis By Indication

8. Global Market Analysis 2017 – 2022 and Forecast 2023 – 2033, By End User 

  8.1. Introduction / Key Findings

  8.2. Historical Market Size (US$ Mn) Analysis By End User, 2017 – 2022

  8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2023 – 2033

    8.3.1. Hospitals

    8.3.2. Academic & Research Institutes

    8.3.3. Ophthalmic Clinics

    8.3.4. Others

  8.4. Market Attractiveness Analysis By End User

9. Global Market Analysis 2017 – 2022 and Forecast 2023 to 2033, by Region

  9.1. Introduction

  9.2. Historical Market Size (US$ Mn) Analysis, By Region, 2017 – 2022

  9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023 – 2033

    9.3.1. North America

    9.3.2. Latin America

    9.3.3. Europe

    9.3.4. South Asia

    9.3.5. East Asia

    9.3.6. Oceania

    9.3.7. Middle East & Africa

  9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  10.1. Introduction

  10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    10.3.1. By Country

      10.3.1.1. USA

      10.3.1.2. Canada

    10.3.2. By Indication

    10.3.3. By End User

  10.4. Market Attractiveness Analysis

    10.4.1. By Country

    10.4.2. By Indication

    10.4.3. By End User

  10.5. Market Trends

  10.6. Market Drivers & Restraints – Impact Analysis

  10.7. Country Level Analysis & Forecast

    10.7.1. USA Market

      10.7.1.1. Introduction

      10.7.1.2. Market Analysis and Forecast by Market Taxonomy

        10.7.1.2.1. By Indication

        10.7.1.2.2. By End User

    10.7.2. Canada Market

      10.7.2.1. Introduction

      10.7.2.2. Market Analysis and Forecast by Market Taxonomy

        10.7.2.2.1. By Indication

        10.7.2.2.2. By End User

11. Latin America Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  11.1. Introduction

  11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    11.3.1. By Country

      11.3.1.1. Brazil

      11.3.1.2. Mexico

      11.3.1.3. Argentina

      11.3.1.4. Rest of LATAM

    11.3.2. By Indication

    11.3.3. By End User

  11.4. Market Attractiveness Analysis

    11.4.1. By Country

    11.4.2. By Indication

    11.4.3. By End User

  11.5. Market Trends

  11.6. Market Drivers & Restraints – Impact Analysis

  11.7. Country Level Analysis & Forecast

    11.7.1. Brazil Market

      11.7.1.1. Introduction

      11.7.1.2. Market Analysis and Forecast by Market Taxonomy

        11.7.1.2.1. By Indication

        11.7.1.2.2. By End User

    11.7.2. Mexico Market

      11.7.2.1. Introduction

      11.7.2.2. Market Analysis and Forecast by Market Taxonomy

        11.7.2.2.1. By Indication

        11.7.2.2.2. By End User

    11.7.3. Argentina Market

      11.7.3.1. Introduction

      11.7.3.2. Market Analysis and Forecast by Market Taxonomy

        11.7.3.2.1. By Indication

        11.7.3.2.2. By End User

12. Europe Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  12.1. Introduction

  12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    12.3.1. By Country

      12.3.1.1. UK

      12.3.1.2. Germany

      12.3.1.3. France

      12.3.1.4. Italy

      12.3.1.5. Spain

      12.3.1.6. BENELUX

      12.3.1.7. Russia

      12.3.1.8. Rest of Europe

    12.3.2. By Indication

    12.3.3. By End User

  12.4. Market Attractiveness Analysis

    12.4.1. By Country

    12.4.2. By Indication

    12.4.3. By End User

  12.5. Market Trends

  12.6. Market Drivers & Restraints – Impact Analysis

  12.7. Country Level Analysis & Forecast

    12.7.1. UK Market

      12.7.1.1. Introduction

      12.7.1.2. Market Analysis and Forecast by Market Taxonomy

        12.7.1.2.1. By Indication

        12.7.1.2.2. By End User

    12.7.2. Germany Market

      12.7.2.1. Introduction

      12.7.2.2. Market Analysis and Forecast by Market Taxonomy

        12.7.2.2.1. By Indication

        12.7.2.2.2. By End User

    12.7.3. France Market

      12.7.3.1. Introduction

      12.7.3.2. Market Analysis and Forecast by Market Taxonomy

        12.7.3.2.1. By Indication

        12.7.3.2.2. By End User

    12.7.4. Italy Market

      12.7.4.1. Introduction

      12.7.4.2. Market Analysis and Forecast by Market Taxonomy

        12.7.4.2.1. By Indication

        12.7.4.2.2. By End User

    12.7.5. Spain Market

      12.7.5.1. Introduction

      12.7.5.2. Market Analysis and Forecast by Market Taxonomy

        12.7.5.2.1. By Indication

        12.7.5.2.2. By End User

    12.7.6. BENELUX Market

      12.7.6.1. Introduction

      12.7.6.2. Market Analysis and Forecast by Market Taxonomy

        12.7.6.2.1. By Indication

        12.7.6.2.2. By End User

    12.7.7. Russia Market

      12.7.7.1. Introduction

      12.7.7.2. Market Analysis and Forecast by Market Taxonomy

        12.7.7.2.1. By Indication

        12.7.7.2.2. By End User

13. East Asia Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  13.1. Introduction

  13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    13.3.1. By Country

      13.3.1.1. China

      13.3.1.2. Japan

      13.3.1.3. South Korea

    13.3.2. By Indication

    13.3.3. By End User

  13.4. Market Attractiveness Analysis

    13.4.1. By Country

    13.4.2. By Indication

    13.4.3. By End User

  13.5. Market Trends

  13.6. Market Drivers & Restraints – Impact Analysis

  13.7. Country Level Analysis & Forecast

    13.7.1. China Market

      13.7.1.1. Introduction

      13.7.1.2. Market Analysis and Forecast by Market Taxonomy

        13.7.1.2.1. By Indication

        13.7.1.2.2. By End User

    13.7.2. Japan Market

      13.7.2.1. Introduction

      13.7.2.2. Market Analysis and Forecast by Market Taxonomy

        13.7.2.2.1. By Indication

        13.7.2.2.2. By End User

    13.7.3. South Korea Market

      13.7.3.1. Introduction

      13.7.3.2. Market Analysis and Forecast by Market Taxonomy

        13.7.3.2.1. By Indication

        13.7.3.2.2. By End User

14. South Asia Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  14.1. Introduction

  14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    14.3.1. By Country

      14.3.1.1. India

      14.3.1.2. Indonesia

      14.3.1.3. Thailand

      14.3.1.4. Malaysia

      14.3.1.5. Rest of South Asia

    14.3.2. By Indication

    14.3.3. By End User

  14.4. Market Attractiveness Analysis

    14.4.1. By Country

    14.4.2. By Indication

    14.4.3. By End User

  14.5. Market Trends

  14.6. Market Drivers & Restraints – Impact Analysis

  14.7. Country Level Analysis & Forecast

    14.7.1. India Market

      14.7.1.1. Introduction

      14.7.1.2. Market Analysis and Forecast by Market Taxonomy

        14.7.1.2.1. By Indication

        14.7.1.2.2. By End User

    14.7.2. Indonesia Market

      14.7.2.1. Introduction

      14.7.2.2. Market Analysis and Forecast by Market Taxonomy

        14.7.2.2.1. By Indication

        14.7.2.2.2. By End User

    14.7.3. Thailand Market

      14.7.3.1. Introduction

      14.7.3.2. Market Analysis and Forecast by Market Taxonomy

        14.7.3.2.1. By Indication

        14.7.3.2.2. By End User

    14.7.4. Malaysia Market

      14.7.4.1. Introduction

      14.7.4.2. Market Analysis and Forecast by Market Taxonomy

        14.7.4.2.1. By Indication

        14.7.4.2.2. By End User

15. Oceania Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  15.1. Introduction

  15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    15.3.1. By Country

      15.3.1.1. Australia

      15.3.1.2. New Zealand

    15.3.2. By Indication

    15.3.3. By End User

  15.4. Market Attractiveness Analysis

    15.4.1. By Country

    15.4.2. By Indication

    15.4.3. By End User

  15.5. Market Trends

  15.6. Market Drivers & Restraints – Impact Analysis

  15.7. Country Level Analysis & Forecast

    15.7.1. Australia Market

      15.7.1.1. Introduction

      15.7.1.2. Market Analysis and Forecast by Market Taxonomy

        15.7.1.2.1. By Indication

        15.7.1.2.2. By End User

    15.7.2. New Zealand Market

      15.7.2.1. Introduction

      15.7.2.2. Market Analysis and Forecast by Market Taxonomy

        15.7.2.2.1. By Indication

        15.7.2.2.2. By End User

16. Middle East & Africa Market Analysis 2017 – 2022 and Forecast 2023 to 2033

  16.1. Introduction

  16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022

  16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033

    16.3.1. By Country

      16.3.1.1. GCC Countries

      16.3.1.2. Türkiye

      16.3.1.3. South Africa

      16.3.1.4. Northern Africa

      16.3.1.5. Rest of Middle East and Africa

    16.3.2. By Indication

    16.3.3. By End User

  16.4. Market Attractiveness Analysis

    16.4.1. By Country

    16.4.2. By Indication

    16.4.3. By End User

  16.5. Market Trends

  16.6. Market Drivers & Restraints – Impact Analysis

  16.7. Country Level Analysis & Forecast

    16.7.1. GCC Countries Market

      16.7.1.1. Introduction

      16.7.1.2. Market Analysis and Forecast by Market Taxonomy

        16.7.1.2.1. By Indication

        16.7.1.2.2. By End User

    16.7.2. Türkiye Market

      16.7.2.1. Introduction

      16.7.2.2. Market Analysis and Forecast by Market Taxonomy

        16.7.2.2.1. By Indication

        16.7.2.2.2. By End User

    16.7.3. South Africa Market

      16.7.3.1. Introduction

      16.7.3.2. Market Analysis and Forecast by Market Taxonomy

        16.7.3.2.1. By Indication

        16.7.3.2.2. By End User

    16.7.4. Northern Africa Market

      16.7.4.1. Introduction

      16.7.4.2. Market Analysis and Forecast by Market Taxonomy

        16.7.4.2.1. By Indication

        16.7.4.2.2. By End User

17. Market Structure Analysis

  17.1. Market Analysis by Tier of Companies (Maternity Care Products)

  17.2. Market Share Analysis of Top Players

  17.3. Market Concentration

18. Competition Analysis

  18.1. Competition Dashboard

  18.2. Branding and Promotional Strategies, By key Players

  18.3. Key Development Analysis

  18.4. Competition Deep Dive

    18.4.1. Gyroscope Therapeutics (Novartis)

      18.4.1.1. Overview

      18.4.1.2. Product Portfolio

      18.4.1.3. Key Financials

      18.4.1.4. SWOT Analysis

      18.4.1.5. Key Developments

      18.4.1.6. Sales Footprint

      18.4.1.7. Strategy Overview

        18.4.1.7.1. Marketing Strategy

        18.4.1.7.2. Product Strategy

        18.4.1.7.3. Channel Strategy

    18.4.2. Applied Genetic Technologies Corporation (AGTC)

      18.4.2.1. Overview

      18.4.2.2. Product Portfolio

      18.4.2.3. Key Financials

      18.4.2.4. SWOT Analysis

      18.4.2.5. Key Developments

      18.4.2.6. Sales Footprint

      18.4.2.7. Strategy Overview

        18.4.2.7.1. Marketing Strategy

        18.4.2.7.2. Product Strategy

        18.4.2.7.3. Channel Strategy

    18.4.3. Spark Therapeutics

      18.4.3.1. Overview

      18.4.3.2. Product Portfolio

      18.4.3.3. Key Financials

      18.4.3.4. SWOT Analysis

      18.4.3.5. Key Developments

      18.4.3.6. Sales Footprint

      18.4.3.7. Strategy Overview

        18.4.3.7.1. Marketing Strategy

        18.4.3.7.2. Product Strategy

        18.4.3.7.3. Channel Strategy

    18.4.4. Adverum Biotechnologies

      18.4.4.1. Overview

      18.4.4.2. Product Portfolio

      18.4.4.3. Key Financials

      18.4.4.4. SWOT Analysis

      18.4.4.5. Key Developments

      18.4.4.6. Sales Footprint

      18.4.4.7. Strategy Overview

        18.4.4.7.1. Marketing Strategy

        18.4.4.7.2. Product Strategy

        18.4.4.7.3. Channel Strategy

    18.4.5. REGENXBIO Inc.

      18.4.5.1. Overview

      18.4.5.2. Product Portfolio

      18.4.5.3. Key Financials

      18.4.5.4. SWOT Analysis

      18.4.5.5. Key Developments

      18.4.5.6. Sales Footprint

      18.4.5.7. Strategy Overview

        18.4.5.7.1. Marketing Strategy

        18.4.5.7.2. Product Strategy

        18.4.5.7.3. Channel Strategy

    18.4.6. Biogen Inc.

      18.4.6.1. Overview

      18.4.6.2. Product Portfolio

      18.4.6.3. Key Financials

      18.4.6.4. SWOT Analysis

      18.4.6.5. Key Developments

      18.4.6.6. Sales Footprint

      18.4.6.7. Strategy Overview

        18.4.6.7.1. Marketing Strategy

        18.4.6.7.2. Product Strategy

        18.4.6.7.3. Channel Strategy

    18.4.7. Nightstar Therapeutics

      18.4.7.1. Overview

      18.4.7.2. Product Portfolio

      18.4.7.3. Key Financials

      18.4.7.4. SWOT Analysis

      18.4.7.5. Key Developments

      18.4.7.6. Sales Footprint

      18.4.7.7. Strategy Overview

        18.4.7.7.1. Marketing Strategy

        18.4.7.7.2. Product Strategy

        18.4.7.7.3. Channel Strategy

    18.4.8. MeiraGTx Holdings plc

      18.4.8.1. Overview

      18.4.8.2. Product Portfolio

      18.4.8.3. Key Financials

      18.4.8.4. SWOT Analysis

      18.4.8.5. Key Developments

      18.4.8.6. Sales Footprint

      18.4.8.7. Strategy Overview

        18.4.8.7.1. Marketing Strategy

        18.4.8.7.2. Product Strategy

        18.4.8.7.3. Channel Strategy

    18.4.9. GenSight Biologics

      18.4.9.1. Overview

      18.4.9.2. Product Portfolio

      18.4.9.3. Key Financials

      18.4.9.4. SWOT Analysis

      18.4.9.5. Key Developments

      18.4.9.6. Sales Footprint

      18.4.9.7. Strategy Overview

        18.4.9.7.1. Marketing Strategy

        18.4.9.7.2. Product Strategy

        18.4.9.7.3. Channel Strategy

    18.4.10. RetroSense Therapeutics

      18.4.10.1. Overview

      18.4.10.2. Product Portfolio

      18.4.10.3. Key Financials

      18.4.10.4. SWOT Analysis

      18.4.10.5. Key Developments

      18.4.10.6. Sales Footprint

      18.4.10.7. Strategy Overview

        18.4.10.7.1. Marketing Strategy

        18.4.10.7.2. Product Strategy

        18.4.10.7.3. Channel Strategy

    18.4.11. Second Sight Medical Products

      18.4.11.1. Overview

      18.4.11.2. Product Portfolio

      18.4.11.3. Key Financials

      18.4.11.4. SWOT Analysis

      18.4.11.5. Key Developments

      18.4.11.6. Sales Footprint

      18.4.11.7. Strategy Overview

        18.4.11.7.1. Marketing Strategy

        18.4.11.7.2. Product Strategy

        18.4.11.7.3. Channel Strategy

    18.4.12. Oxford Biomedica

      18.4.12.1. Overview

      18.4.12.2. Product Portfolio

      18.4.12.3. Key Financials

      18.4.12.4. SWOT Analysis

      18.4.12.5. Key Developments

      18.4.12.6. Sales Footprint

      18.4.12.7. Strategy Overview

        18.4.12.7.1. Marketing Strategy

        18.4.12.7.2. Product Strategy

        18.4.12.7.3. Channel Strategy

    18.4.13. Hemera Biosciences

      18.4.13.1. Overview

      18.4.13.2. Product Portfolio

      18.4.13.3. Key Financials

      18.4.13.4. SWOT Analysis

      18.4.13.5. Key Developments

      18.4.13.6. Sales Footprint

      18.4.13.7. Strategy Overview

        18.4.13.7.1. Marketing Strategy

        18.4.13.7.2. Product Strategy

        18.4.13.7.3. Channel Strategy

    18.4.14. Adverio Pharmaceuticals

      18.4.14.1. Overview

      18.4.14.2. Product Portfolio

      18.4.14.3. Key Financials

      18.4.14.4. SWOT Analysis

      18.4.14.5. Key Developments

      18.4.14.6. Sales Footprint

      18.4.14.7. Strategy Overview

        18.4.14.7.1. Marketing Strategy

        18.4.14.7.2. Product Strategy

        18.4.14.7.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Gene Therapy in CNS Disorder Market

Published : February 2023

Healthcare

Retinal Vein Occlusion Treatment Market

Published : January 2023

Healthcare

Retinal Biologics Market

Published : July 2022

Explore Healthcare Insights

View Reports

Retinal Gene Therapy Market